A study from researchers at the Massachusetts General Hospital (MGH) Cancer Center has demonstrated how the response to pancreatic cancer cells of normal tissue - called the stroma - within tumours can influence the ability of individual cancer cells to proliferate and metastasise.
Their report, which details how differences in the relative amounts of tumour cells and stromal cells alter patterns of gene expression within individual tumour cells, is being published in Cell and may lead to improved therapies for this difficult-to-treat cancer.
"Our finding that pancreatic cancer cells can behave differently based on the types of cells that are around them may explain why some cells respond to chemotherapy and radiation and some do not," says David Ting, MD, of the Tucker Gosnell Center for Gastrointestinal Malignancies in the MGH Cancer Center, co-senior author of the report
"We also identified a unique cell type that has the ability to replicate and to move at the same time, activates both the MAPK and STAT3 signalling pathways and is killed by combined use of MAPK and STAT3 inhibitors, suggesting a potential therapeutic strategy."
The stroma of pancreatic tumours largely consists of connective tissue cells called cancer-associated fibroblasts (CAFs), along with immune cells and endothelial cells.
While some studies have suggested that pancreatic CAFs contribute to the growth and spread of cancer, others have found that reducing CAFs led to more aggressive tumour behaviour.
These findings, along with the variability of stromal content within pancreatic tumours, suggested that interactions between CAFs and tumour cells are complex.
Recent studies by the MGH team found significant differences in gene expression between pancreatic cancer cells in the primary tumour and those circulating in the bloodstream, with some expressing signatures indicating proliferative features and others more metastatic potential.
Subpopulations of cancers cells at the interface between tumour and stroma also expressed these differing genetic signatures, suggesting that they might be influenced by CAFs in the stroma.
The team's current experiments revealed that:
"The assay we developed to identify these different tumour glands provides a strategy to use it as a biomarker to select personalise therapy based on the response of normal cells to the cancer," says Ting, who is an assistant professor of Medicine at Harvard Medical School.
"The identification of the roles of both MAPK and STAT3 signalling in generating the different classes of PDACs and the role of CAF-secreted TGF-β in that signalling suggests the importance of investigating how different stromal compositions may determine the optimal drug combinations."
Source: Massachusetts General Hospital